Dry eye also was an area of high interest, particularly a study comparing omega-3 fatty acids with olive oil.
The country plans to increase surgical volume by 80 percent.
CMS data indicate that Anthem’s denial of monitored anesthesia care would have
a big impact on surgeons.
The South American country’s economic crisis forces one surgeon to plan to leave.
Regulators set a May 8 deadline for Takeda to make a firm offer.
The move bolster’s the firm’s position in sustained-release technology.
The company said the name change reflects its broader product offering.
The failed merger comes after a downturn in revenues for Akorn.
The new standards classify medical devices into four categories, each with its own local content requirement.
Freedom Ophthalmic is building a new factory to expand into pharmaceuticals.
Severely hyperopic patient had a shallow chamber and high intraocular pressure from angle-closure glaucoma.
The drug’s pass-through status expired Dec. 31. It restarts Oct. 1, 2018.
The device is designed to provide a screening test during a routine office visit in a primary care setting.
Aerie announced that it planned to launch Rhopressa for glaucoma in May, while Kala reported positive Phase III results for its dry eye candidate, KPI-121.
The segment is expected to grow at rate of 4 percent through 2023.
Factors driving growth include more government and private spending and an expanding elderly population.
The suit alleges that the Hydrus Microstent infringes two Glaukos patents that protect a method of treating glaucoma using Schlemm’s canal.
The US patent board had planned to render a final decision on the patentability of the challenged patents by June 6.
The company recommended that doctors not use Eylea kits with certain lot numbers.
The study used a stand-alone procedure to avoid the confounding effect of cataract surgery.
You are not currently logged in.
©2018 Market Scope
Lost your Password